Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent.

Toma M, Witusik-Perkowska M, Szwed M, Stawski R, Szemraj J, Drzewiecka M, Nieborowska-Skorska M, Radek M, Kolasa P, Matlawska-Wasowska K, Sliwinski T, Skorski T.

Oncotarget. 2018 Dec 7;9(96):36867-36877. doi: 10.18632/oncotarget.26409. eCollection 2018 Dec 7.

2.

Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia.

Nieborowska-Skorska M, Maifrede S, Ye M, Toma M, Hewlett E, Gordon J, Le BV, Sliwinski T, Zhao H, Piwocka K, Valent P, Tulin AV, Childers W, Skorski T.

Leuk Lymphoma. 2019 Apr;60(4):1098-1101. doi: 10.1080/10428194.2018.1520988. Epub 2018 Oct 2. No abstract available.

PMID:
30277116
3.

PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions.

Podszywalow-Bartnicka P, Maifrede S, Le BV, Nieborowska-Skorska M, Piwocka K, Skorski T.

Leuk Lymphoma. 2019 Jan;60(1):262-264. doi: 10.1080/10428194.2018.1471602. Epub 2018 Jun 22. No abstract available.

PMID:
29932782
4.

Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.

Sullivan-Reed K, Bolton-Gillespie E, Dasgupta Y, Langer S, Siciliano M, Nieborowska-Skorska M, Hanamshet K, Belyaeva EA, Bernhardy AJ, Lee J, Moore M, Zhao H, Valent P, Matlawska-Wasowska K, Müschen M, Bhatia S, Bhatia R, Johnson N, Wasik MA, Mazin AV, Skorski T.

Cell Rep. 2018 Jun 12;23(11):3127-3136. doi: 10.1016/j.celrep.2018.05.034.

5.

Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.

Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik MA, Huang J, Skorski T.

Blood. 2018 Jul 5;132(1):67-77. doi: 10.1182/blood-2018-02-834895. Epub 2018 May 21.

PMID:
29784639
6.

MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs.

Maifrede S, Martinez E, Nieborowska-Skorska M, Di Marcantonio D, Hulse M, Le BV, Zhao H, Piwocka K, Tempera I, Sykes SM, Skorski T.

Blood Adv. 2017 Aug 9;1(19):1467-1472. doi: 10.1182/bloodadvances.2017006247. eCollection 2017 Aug 22.

7.

Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia.

Di Marcantonio D, Martinez E, Sidoli S, Vadaketh J, Nieborowska-Skorska M, Gupta A, Meadows JM, Ferraro F, Masselli E, Challen GA, Milsom MD, Scholl C, Fröhling S, Balachandran S, Skorski T, Garcia BA, Mirandola P, Gobbi G, Garzon R, Vitale M, Sykes SM.

Clin Cancer Res. 2018 Feb 1;24(3):608-618. doi: 10.1158/1078-0432.CCR-17-2684. Epub 2017 Nov 10.

8.

Drugging DNA repair to target T-ALL cells.

Dasgupta Y, Golovine K, Nieborowska-Skorska M, Luo L, Matlawska-Wasowska K, Mullighan CG, Skorski T.

Leuk Lymphoma. 2018 Jul;59(7):1746-1749. doi: 10.1080/10428194.2017.1397662. Epub 2017 Nov 8. No abstract available.

9.

Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.

Nieborowska-Skorska M, Maifrede S, Dasgupta Y, Sullivan K, Flis S, Le BV, Solecka M, Belyaeva EA, Kubovcakova L, Nawrocki M, Kirschner M, Zhao H, Prchal JT, Piwocka K, Moliterno AR, Wasik M, Koschmieder S, Green TR, Skoda RC, Skorski T.

Blood. 2017 Dec 28;130(26):2848-2859. doi: 10.1182/blood-2017-05-784942. Epub 2017 Oct 17.

10.

IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.

Maifrede S, Martin K, Podszywalow-Bartnicka P, Sullivan-Reed K, Langer SK, Nejati R, Dasgupta Y, Hulse M, Gritsyuk D, Nieborowska-Skorska M, Lupey-Green LN, Zhao H, Piwocka K, Wasik MA, Tempera I, Skorski T.

Mol Cancer Res. 2017 Aug;15(8):967-972. doi: 10.1158/1541-7786.MCR-16-0468. Epub 2017 Jun 20.

11.

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JC, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T.

J Clin Invest. 2017 Jun 1;127(6):2392-2406. doi: 10.1172/JCI90825. Epub 2017 May 8.

12.

Increased phosphorylation of eIF2α in chronic myeloid leukemia cells stimulates secretion of matrix modifying enzymes.

Podszywalow-Bartnicka P, Cmoch A, Wolczyk M, Bugajski L, Tkaczyk M, Dadlez M, Nieborowska-Skorska M, Koromilas AE, Skorski T, Piwocka K.

Oncotarget. 2016 Nov 29;7(48):79706-79721. doi: 10.18632/oncotarget.12941.

13.

Inhibition of human glioma cell proliferation by altered Bax/Bcl-2-p53 expression and apoptosis induction by Rhaponticum carthamoides extracts from transformed and normal roots.

Skała E, Sitarek P, Toma M, Szemraj J, Radek M, Nieborowska-Skorska M, Skorski T, Wysokińska H, Śliwiński T.

J Pharm Pharmacol. 2016 Nov;68(11):1454-1464. doi: 10.1111/jphp.12619. Epub 2016 Oct 2.

PMID:
27696406
14.

PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.

Czyż M, Toma M, Gajos-Michniewicz A, Majchrzak K, Hoser G, Szemraj J, Nieborowska-Skorska M, Cheng P, Gritsyuk D, Levesque M, Dummer R, Sliwinski T, Skorski T.

Oncotarget. 2016 Nov 15;7(46):75551-75560. doi: 10.18632/oncotarget.12270.

15.

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.

Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T.

Blood. 2016 Apr 28;127(17):2131-43. doi: 10.1182/blood-2015-11-681171. Epub 2016 Feb 10.

16.

A preliminary study of apoptosis induction in glioma cells via alteration of the Bax/Bcl-2-p53 axis by transformed and non-transformed root extracts of Leonurus sibiricus L.

Sitarek P, Skała E, Toma M, Wielanek M, Szemraj J, Nieborowska-Skorska M, Kolasa M, Skorski T, Wysokińska H, Śliwiński T.

Tumour Biol. 2016 Jul;37(7):8753-64. doi: 10.1007/s13277-015-4714-2. Epub 2016 Jan 7.

PMID:
26743778
17.

Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation.

Podszywalow-Bartnicka P, Wolczyk M, Kusio-Kobialka M, Wolanin K, Skowronek K, Nieborowska-Skorska M, Dasgupta Y, Skorski T, Piwocka K.

Cell Cycle. 2014;13(23):3727-41. doi: 10.4161/15384101.2014.965013.

PMID:
25483082
18.

AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells.

Nieborowska-Skorska M, Flis S, Skorski T.

Leukemia. 2014 Dec;28(12):2416-8. doi: 10.1038/leu.2014.249. Epub 2014 Aug 25. No abstract available.

19.

Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.

Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, Slupianek A, Rassool FV, Wasik MA, Childers W, Copland M, Müschen M, Civin CI, Skorski T.

Blood. 2013 Aug 15;122(7):1293-304. doi: 10.1182/blood-2013-05-501072. Epub 2013 Jul 8.

20.

Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice.

Nieborowska-Skorska M, Hoser G, Hochhaus A, Stoklosa T, Skorski T.

Leukemia. 2013 Nov;27(11):2253-4. doi: 10.1038/leu.2013.123. Epub 2013 Apr 22. No abstract available.

21.

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.

Bolton-Gillespie E, Schemionek M, Klein HU, Flis S, Hoser G, Lange T, Nieborowska-Skorska M, Maier J, Kerstiens L, Koptyra M, Müller MC, Modi H, Stoklosa T, Seferynska I, Bhatia R, Holyoake TL, Koschmieder S, Skorski T.

Blood. 2013 May 16;121(20):4175-83. doi: 10.1182/blood-2012-11-466938. Epub 2013 Mar 29.

22.

Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.

Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, Cramer K, Reddy MM, Koptyra M, Penserga T, Glodkowska-Mrowka E, Bolton E, Holyoake TL, Eaves CJ, Cerny-Reiterer S, Valent P, Hochhaus A, Hughes TP, van der Kuip H, Sattler M, Wiktor-Jedrzejczak W, Richardson C, Dorrance A, Stoklosa T, Williams DA, Skorski T.

Blood. 2012 May 3;119(18):4253-63. doi: 10.1182/blood-2011-10-385658. Epub 2012 Mar 12.

23.

BCR-ABL1 kinase facilitates localization of acetylated histones 3 and 4 on DNA double-strand breaks.

Falinski R, Nieborowska-Skorska M, Skorski T.

Leuk Res. 2012 Feb;36(2):241-4. doi: 10.1016/j.leukres.2011.10.007. Epub 2011 Oct 28.

24.

Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.

Slupianek A, Dasgupta Y, Ren SY, Gurdek E, Donlin M, Nieborowska-Skorska M, Fleury F, Skorski T.

Blood. 2011 Jul 28;118(4):1062-8. doi: 10.1182/blood-2010-09-307256. Epub 2011 Jun 7.

25.

BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair.

Cramer K, Nieborowska-Skorska M, Koptyra M, Slupianek A, Penserga ET, Eaves CJ, Aulitzky W, Skorski T.

Cancer Res. 2008 Sep 1;68(17):6884-8. doi: 10.1158/0008-5472.CAN-08-1101.

26.

BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations.

Stoklosa T, Poplawski T, Koptyra M, Nieborowska-Skorska M, Basak G, Slupianek A, Rayevskaya M, Seferynska I, Herrera L, Blasiak J, Skorski T.

Cancer Res. 2008 Apr 15;68(8):2576-80. doi: 10.1158/0008-5472.CAN-07-6858.

27.

Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells.

Rink L, Slupianek A, Stoklosa T, Nieborowska-Skorska M, Urbanska K, Seferynska I, Reiss K, Skorski T.

Blood. 2007 Jul 15;110(2):651-60. Epub 2007 Apr 12.

28.

ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks.

Nieborowska-Skorska M, Stoklosa T, Datta M, Czechowska A, Rink L, Slupianek A, Koptyra M, Seferynska I, Krszyna K, Blasiak J, Skorski T.

Cell Cycle. 2006 May;5(9):994-1000. Epub 2006 May 1.

PMID:
16687921
29.

Id1 transcription inhibitor-matrix metalloproteinase 9 axis enhances invasiveness of the breakpoint cluster region/abelson tyrosine kinase-transformed leukemia cells.

Nieborowska-Skorska M, Hoser G, Rink L, Malecki M, Kossev P, Wasik MA, Skorski T.

Cancer Res. 2006 Apr 15;66(8):4108-16.

30.

BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.

Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M, Blasiak J, Skorski T.

Blood. 2006 Jul 1;108(1):319-27. Epub 2006 Mar 9.

31.

BCR/ABL recruits p53 tumor suppressor protein to induce drug resistance.

Stoklosa T, Slupianek A, Datta M, Nieborowska-Skorska M, Nowicki MO, Koptyra M, Skorski T.

Cell Cycle. 2004 Nov;3(11):1463-72. Epub 2004 Nov 10.

PMID:
15492510
32.

BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks.

Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E, Nieborowska-Skorska M, Blasiak J, Skorski T.

Blood. 2004 Dec 1;104(12):3746-53. Epub 2004 Aug 10.

33.

The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.

Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE, Skorski T.

EMBO J. 2002 Nov 1;21(21):5766-74.

34.

Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis.

Nieborowska-Skorska M, Hoser G, Kossev P, Wasik MA, Skorski T.

Blood. 2002 Jun 15;99(12):4531-9.

35.

BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance.

Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO, Pierce AJ, Fishel R, Skorski T.

Mol Cell. 2001 Oct;8(4):795-806.

36.

Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.

Nieborowska-Skorska M, Slupianek A, Xue L, Zhang Q, Raghunath PN, Hoser G, Wasik MA, Morris SW, Skorski T.

Cancer Res. 2001 Sep 1;61(17):6517-23.

37.

Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.

Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, Morris SW, Wasik MA, Skorski T.

Cancer Res. 2001 Mar 1;61(5):2194-9.

38.

Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.

Nieborowska-Skorska M, Slupianek A, Skorski T.

Oncogene. 2000 Aug 24;19(36):4117-24.

39.

Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt.

Majewski M, Nieborowska-Skorska M, Salomoni P, Slupianek A, Reiss K, Trotta R, Calabretta B, Skorski T.

Cancer Res. 1999 Jun 15;59(12):2815-9.

40.

Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis.

Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, Skorski T.

J Exp Med. 1999 Apr 19;189(8):1229-42.

41.

BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac.

Skorski T, Wlodarski P, Daheron L, Salomoni P, Nieborowska-Skorska M, Majewski M, Wasik M, Calabretta B.

Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11858-62.

42.

The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing.

Skorski T, Nieborowska-Skorska M, Wlodarski P, Wasik M, Trotta R, Kanakaraj P, Salomoni P, Antonyak M, Martinez R, Majewski M, Wong A, Perussia B, Calabretta B.

Blood. 1998 Jan 15;91(2):406-18.

43.

Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, Calabretta B.

EMBO J. 1997 Oct 15;16(20):6151-61.

44.

Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells.

de Fabritiis P, Skorski T, De Propris MS, Paggi MG, Nieborowska-Skorska M, Lisci A, Buffolino S, Campbell K, Geiser T, Calabretta B.

Leukemia. 1997 Jun;11(6):811-9.

PMID:
9177433
45.

Antileukemia effect of c-myc N3'-->P5' phosphoramidate antisense oligonucleotides in vivo.

Skorski T, Perrotti D, Nieborowska-Skorska M, Gryaznov S, Calabretta B.

Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3966-71.

46.

Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.

Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Hoser G, Kawiak J, Majewski M, Christensen L, Iozzo RV, Calabretta B.

J Natl Cancer Inst. 1997 Jan 15;89(2):124-33.

PMID:
8998181
47.

Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase.

Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Martinez R, Wasik MA, Calabretta B.

Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13137-42.

48.

Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.

Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, Iozzo RV, Calabretta B.

Blood. 1996 Aug 1;88(3):1005-12.

49.

Oligonucleotide N3'-->P5' phosphoramidates as antisense agents.

Gryaznov S, Skorski T, Cucco C, Nieborowska-Skorska M, Chiu CY, Lloyd D, Chen JK, Koziolkiewicz M, Calabretta B.

Nucleic Acids Res. 1996 Apr 15;24(8):1508-14.

50.

The influence of phosphorothioate oligodeoxynucleotides on various organs in vivo.

Nieborowska-Skórska M, Białek AP, Nicolaides NC, Iozzo RV, Kawalec M, Calabretta B, Kawiak J, Marlicz K, Skórski T.

Folia Histochem Cytobiol. 1996;34(2):69-73.

PMID:
8875213

Supplemental Content

Loading ...
Support Center